MARKET

BOLD

Audentes
BOLD
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-17.6154
-
7.15
2,745,622,402.05
About BOLD
Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company's subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.
More

BOLD News

More
Will Johnson & Johnson Acquire Arrowhead Pharmaceuticals?
Will the pharma giant be interested in acquiring a mid-cap partner with a promising treatment for hepatitis B?
Motley Fool · 06/02 16:35
Astellas Pharma Inc. -- Moody's downgrades Astellas's issuer rating to A2; outlook negative
Moody's · 03/05 12:35
Paul Tudor Jones' Firm Buys Caesars Entertainment, Audentes Therapeutics
GuruFocus.com · 02/20 17:22
Steven Cohen Renews His Interest in Verastem
GuruFocus.com · 02/05 16:52
2019 Review: Most Favored Hedge Fund Stocks vs. Audentes Therapeutics, Inc. (BOLD)
Insider Monkey · 01/12 22:38
AMAG to Sell Women Healthcare Drugs, CEO Resigns, Stock Down
Zacks · 01/10 23:08
Agenus Initiates Phase I Study on Oncology Candidate AGEN1223
Zacks · 01/09 14:48
The Daily Biotech Pulse: Xeris Jumps On Positive Data, Mixed Results For Merck's Keytruda-Chemo Combo In Lung Cancer, Intra-Cellular Announces Offering
The following is a roundup of top developments in the biotech space over the last 24 hours.  Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 6.)
Benzinga · 01/07 12:57

Hot Stocks

Symbol
Price
%Change

Webull offers kinds of Audentes stock information, including NASDAQ:BOLD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BOLD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BOLD stock methods without spending real money on the virtual paper trading platform.